150.85
前日終値:
$159.12
開ける:
$157.54
24時間の取引高:
1.40M
Relative Volume:
1.38
時価総額:
$7.27B
収益:
$4.02B
当期純損益:
$-142.16M
株価収益率:
-51.03
EPS:
-2.9563
ネットキャッシュフロー:
$518.49M
1週間 パフォーマンス:
-15.07%
1か月 パフォーマンス:
-16.45%
6か月 パフォーマンス:
-10.11%
1年 パフォーマンス:
+8.61%
Charles River Laboratories International Inc Stock (CRL) Company Profile
名前
Charles River Laboratories International Inc
セクター
電話
781-222-6000
住所
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, WAT, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International Inc
|
150.85 | 7.66B | 4.02B | -142.16M | 518.49M | -2.9563 |
|
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
|
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
|
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-11-17 | アップグレード | Argus | Hold → Buy |
| 2025-11-06 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-09-09 | アップグレード | Jefferies | Hold → Buy |
| 2025-07-09 | アップグレード | Citigroup | Neutral → Buy |
| 2025-05-23 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | アップグレード | TD Cowen | Hold → Buy |
| 2025-05-08 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-03-21 | ダウングレード | Goldman | Buy → Neutral |
| 2025-03-04 | アップグレード | Citigroup | Sell → Neutral |
| 2025-03-03 | アップグレード | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | ダウングレード | UBS | Buy → Neutral |
| 2024-11-18 | ダウングレード | CLSA | Hold → Underperform |
| 2024-11-07 | アップグレード | CLSA | Underperform → Hold |
| 2024-10-23 | 開始されました | CLSA | Underperform |
| 2024-10-14 | 開始されました | Redburn Atlantic | Sell |
| 2024-10-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-10-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-01 | ダウングレード | Citigroup | Neutral → Sell |
| 2024-08-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-08-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | ダウングレード | Argus | Buy → Hold |
| 2024-06-07 | 開始されました | Mizuho | Neutral |
| 2024-06-06 | 開始されました | Goldman | Buy |
| 2024-02-15 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-09-13 | 開始されました | TD Cowen | Market Perform |
| 2023-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-02-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-01-12 | ダウングレード | Jefferies | Buy → Hold |
| 2022-09-30 | アップグレード | Jefferies | Hold → Buy |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-08-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 開始されました | Guggenheim | Neutral |
| 2022-04-25 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-07 | 開始されました | Stephens | Overweight |
| 2022-02-17 | 繰り返されました | BofA Securities | Buy |
| 2022-02-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-02-17 | 繰り返されました | Deutsche Bank | Buy |
| 2022-02-17 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-17 | 繰り返されました | UBS | Buy |
| 2021-08-05 | 再開されました | Credit Suisse | Neutral |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-09-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-07-01 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-05-13 | アップグレード | UBS | Neutral → Buy |
| 2020-04-21 | ダウングレード | Jefferies | Buy → Hold |
| 2020-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 開始されました | Deutsche Bank | Buy |
| 2020-02-18 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | アップグレード | Goldman | Neutral → Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-10-18 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 開始されました | SVB Leerink | Outperform |
| 2019-04-30 | 再開されました | Evercore ISI | Outperform |
| 2018-12-14 | 開始されました | Deutsche Bank | Buy |
| 2018-10-09 | 開始されました | UBS | Neutral |
| 2018-08-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | アップグレード | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Charles River Laboratories International Inc (CRL) 最新ニュース
Charles River Laboratories Tops Q3 Estimates, Tightens Full-Year Outlook - MSN
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform - simplywall.st
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MSN
Charles River (CRL) reliance on international sales: What investors need to know - MSN
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Director Nancy Andrews gifts Charles River (CRL) shares to trust - Stock Titan
Charles River Laboratories stock (US1591881009): Q1 earnings beat with updated FY guidance - AD HOC NEWS
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - BioSpace
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River Laboratories stock (US1591881009): Shareholders approve 2026 incentive plan - AD HOC NEWS
Charles River (CRL) Partners with Medipost for Cell Therapy Adva - GuruFocus
Charles River Laboratories (CRL) Announces Approval of 2026 Long-Term Incentive Plan - GuruFocus
Director Steven Barg receives 1,438-share equity award at Charles River (NYSE: CRL) - Stock Titan
Charles River Labs (CRL) director receives 1,438-share equity award grant - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock grant - Stock Titan
Charles River Laboratories stock (US1591881009): Q1 earnings beat but FY2026 forecast cut - AD HOC NEWS
Number of shareholders of Charles River Laboratories International, Inc. – HAM:RV6 - TradingView
Charles River Laboratories International Inc (CRL) Stock Down 5. - GuruFocus
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down - MSN
Charles River Labs Shareholders Approve New Incentive Plan - TipRanks
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River (NYSE: CRL) investors approve 2026 incentive plan, pay and auditor - Stock Titan
Charles River (NYSE: CRL) director Abraham Ceesay receives 1,438-share stock grant - Stock Titan
Charles River Labs (NYSE: CRL) director Martin Mackay receives new stock grants - Stock Titan
Director at Charles River (NYSE: CRL) gets 1,438-share equity grant - Stock Titan
Charles River (NYSE: CRL) director receives stock grants instead of fees - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock award - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,973-share equity award - Stock Titan
Director Virginia M. Wilson (CRL) receives 1,438-share equity award at Charles River - Stock Titan
Director James Foster gets 1,860 Charles River (NYSE: CRL) shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Charles River (CRL) Enhances Digital Pathology Platform for Fast - GuruFocus
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow - 01net
Charles River (CRL) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Charles River expands AI-enabled digital pathology platform By Investing.com - Investing.com Canada
Charles River Laboratories stock (US1591881009): Core business and market position - AD HOC NEWS
Charles River Laboratories stock: Is CRL underperforming the healthcare sector? - MSN
Is It Time To Rethink Charles River Laboratories (CRL) After Its Recent Price Rebound? - Yahoo Finance
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum - simplywall.st
Charles River Laboratories International Q1 Earnings Call Highlights - Barchart.com
MSN Money - MSN
Charles River Laboratories stock (US1591881009): Shares dip after recent run-up as analysts eye upsi - AD HOC NEWS
Charles River Laboratories Q1 2026 earnings preview - MSN
These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results - Benzinga
Charles River Laboratories International, Inc. Seeks M&A Opportunities - marketscreener.com
Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2026 Earnings Call Transcript - Insider Monkey
Mizuho raises Charles River Labs stock price target on steady results - Investing.com Canada
Charles River: Q1 Earnings Snapshot - theheraldreview.com
Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance - Moomoo
Johnson Opportunity Fund's Charles River Laboratories International Inc(CRL) Holding History - GuruFocus
Charles River Laboratories International Inc (CRL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):